ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

NCI Plans to Fund FY 1985 R01s, P01s with Cuts 2.9-3.8% Under Recommended Groups, Centers Reduced 7-10%

March 16, 1984

In Brief: Comprehensive Designation To MN Center; Bernardin Center Wins NCI Planning Grant

October 16, 1998

BMS Settles Charges Of Obstructing Generics

March 14, 2003

In Brief: Congressional Action Imminent On Cancer Ac Renewal, Hew Money Bills; Veto Threatened

September 8, 1978

Pennsylvania Issues RFPs For Cancer Control Program

October 21, 1983

Wynder, Doll, Hill Share Ochsner Award

September 23, 1988